{
    "clinical_study": {
        "@rank": "6695", 
        "arm_group": [
            {
                "arm_group_label": "levofloxacin and solifenacin succinate", 
                "arm_group_type": "Experimental", 
                "description": "Levofloxacin 500 mg tablet and solifenacin succinate 5 mg tablet by mouth once daily for 3 days"
            }, 
            {
                "arm_group_label": "levofloxacin and placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Levofloxacin 500 mg tablet and placebo (for solifenacin succinate) by mouth once daily for 3 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg)\n      for short-term treatment to reduce symptoms in patients with symptomatic non complicated\n      urinary tract infection in females."
        }, 
        "brief_title": "The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Urinary Tract Infection", 
        "condition_browse": {
            "mesh_term": "Urinary Tract Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  females (18-65 years old)\n\n          -  dysuria in symptomatic non complicated urinary tract infection\n\n        Exclusion Criteria:\n\n          -  Pediatric Patients (< 18 years old)\n\n          -  geriatric Patients (> 65 years old)\n\n          -  pregnant Patients\n\n          -  Patients with complicated urinary tract infection\n\n          -  sexually transmitted infections\n\n          -  Patients with pathological abnormalities in the urinary bladder, including stone/mass\n\n          -  Catheter-mounted\n\n          -  Neurological diseases/disorders\n\n          -  patients with allergy/hypersensitivity with Levofloxacin/Solifenacin"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094703", 
            "org_study_id": "URO-SOL-01-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "levofloxacin and solifenacin succinate", 
                    "levofloxacin and placebo"
                ], 
                "intervention_name": "Levofloxacin", 
                "intervention_type": "Drug", 
                "other_name": "neslav"
            }, 
            {
                "arm_group_label": "levofloxacin and solifenacin succinate", 
                "intervention_name": "Solifenacin succinate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "levofloxacin and placebo", 
                "intervention_name": "Placebo (for Solifenacin succinate)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ofloxacin", 
                "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "female", 
            "age 18-65 years", 
            "storage symptoms", 
            "clinical urinary tract infection", 
            "non complicated"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "contact": {
                "email": "harrinaerlianti@yahoo.com", 
                "last_name": "Harrina Erlianti Rahardjo", 
                "phone": "+62 816-825-226"
            }, 
            "facility": {
                "address": {
                    "city": "Jakarta", 
                    "country": "Indonesia", 
                    "zip": "10430"
                }, 
                "name": "Cipto Mangunkusumo Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Indonesia: Departement Kesehatan (Ministry of Health)"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with storage symptoms", 
            "safety_issue": "No", 
            "time_frame": "up to three days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094703"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dr Cipto Mangunkusumo General Hospital", 
            "investigator_full_name": "Harrina Erlianti Rahardjo,MD,PhD", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Dr Cipto Mangunkusumo General Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Astellas Pharma Indonesia Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Pharos Life Corporation", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Dr Cipto Mangunkusumo General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}